Patents by Inventor Carlo M. Croce

Carlo M. Croce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10584144
    Abstract: The presently-disclosed subject matter relates to an artificial RNA nanostructure molecule and method to treat brain tumor in a subject. More particularly, the presently disclosed subject matter relates to a RNA nanostructure containing a multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent. Further, the presently disclosed subject matter relates to a method of using the RNA nanostructure composition to treat brain tumor in a subject having or at risk of having brain tumor.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 10, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Carlo M. Croce, Tae Jin Lee, Farzin Haque, Hui Li
  • Publication number: 20190106452
    Abstract: The presently-disclosed subject matter relates to an artificial RNA nanostructure molecule and method to treat brain tumor in a subject. More particularly, the presently disclosed subject matter relates to a RNA nanostructure containing a multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent. Further, the presently disclosed subject matter relates to a method of using the RNA nanostructure composition to treat brain tumor in a subject having or at risk of having brain tumor.
    Type: Application
    Filed: March 9, 2016
    Publication date: April 11, 2019
    Inventors: Peixuan Guo, Carlo M. Croce, Tae Jin Lee, Farzin Haque, Hui Li
  • Publication number: 20190055557
    Abstract: The present invention relates, in various embodiments, to methods of treating cachexia (e.g., cancer cachexia) in a patient. The methods comprise administering at least one compound for inhibiting, in alternative embodiments, the expression or activity of a microRNA that is present in microvesicles secreted from cancer cells in the patient (e.g., a miR-21 gene product), the expression or activity of a Toll-like receptor (e.g., TLR7, TLR8), the expression or activity of a c-Jun N-terminal kinase (JNK), the secretion of microvesicles from cancer cells, or the fusion of microvesicles from cancer cells with muscle cells or adipocytes. The present invention also relates, in certain embodiments, to pharmaceutical compositions comprising at least two compounds useful in the practice of the methods of the invention described herein.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 21, 2019
    Inventors: Carlo M. Croce, Denis C. Guttridge
  • Patent number: 10036018
    Abstract: The present invention relates, in various embodiments, to methods of treating cachexia (e.g., cancer cachexia) in a patient. The methods comprise administering at least one compound for inhibiting, in alternative embodiments, the expression or activity of a microRNA that is present in microvesicles secreted from cancer cells in the patient (e.g., a miR-21 gene product), the expression or activity of a Toll-like receptor (e.g., TLR7, TLR8), the expression or activity of a c-Jun N-terminal kinase (JNK), the secretion of microvesicles from cancer cells, or the fusion of microvesicles from cancer cells with muscle cells or adipocytes. The present invention also relates, in certain embodiments, to pharmaceutical compositions comprising at least two compounds useful in the practice of the methods of the invention described herein.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 31, 2018
    Inventors: Carlo M. Croce, Denis C. Guttridge
  • Publication number: 20170275625
    Abstract: Described herein are methods and compositions for the treatment of colon cancers.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 28, 2017
    Applicants: The Ohio State University Research Foundation, The Government of the United States of America, as represented by the Secretary of the Department of
    Inventors: Carlo M. Croce, Curtis C. Harris, Aaron J. Schetter
  • Publication number: 20170211066
    Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Applicants: The Ohio State University Research Foundation, The Government of the United States of America, as represented by the Secretary of the Department of
    Inventors: Carlo M. Croce, Stefan Ambs
  • Patent number: 9713625
    Abstract: Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 25, 2017
    Assignee: The Ohio State University
    Inventors: Carlo M. Croce, Andrea Vecchione
  • Publication number: 20170175123
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: August 15, 2016
    Publication date: June 22, 2017
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 9574239
    Abstract: Described herein are methods and compositions for the diagnosis, prognosis and treatment of ovarian cancer. Also described are methods of identifying anti-cancer agents.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: February 21, 2017
    Assignee: The Ohio State University Research Foundation
    Inventor: Carlo M. Croce
  • Publication number: 20170037412
    Abstract: Methods and compositions for the diagnosis, prognosis and/or treatment of ovarian cancer are disclosed.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 9, 2017
    Applicant: The Ohio State University
    Inventors: David E. Cohn, Kimberly E. Resnick, Hansjuerg Alder, Carlo M. Croce
  • Publication number: 20170015996
    Abstract: The present invention relates, in various embodiments, to methods of treating cachexia (e.g., cancer cachexia) in a patient. The methods comprise administering at least one compound for inhibiting, in alternative embodiments, the expression or activity of a microRNA that is present in microvesicles secreted from cancer cells in the patient (e.g., a miR-21 gene product), the expression or activity of a Toll-like receptor (e.g., TLR7, TLR8), the expression or activity of a c-Jun N-terminal kinase (JNK), the secretion of microvesicles from cancer cells, or the fusion of microvesicles from cancer cells with muscle cells or adipocytes. The present invention also relates, in certain embodiments, to pharmaceutical compositions comprising at least two compounds useful in the practice of the methods of the invention described herein.
    Type: Application
    Filed: March 10, 2015
    Publication date: January 19, 2017
    Inventors: Carlo M. Croce, Denis C. Guttridge
  • Publication number: 20170002353
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Toll-like receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Publication number: 20160375107
    Abstract: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorders using the Fhit gene.
    Type: Application
    Filed: September 13, 2016
    Publication date: December 29, 2016
    Applicant: The Ohio State University
    Inventors: Carlo M. Croce, Francesco Trapasso
  • Patent number: 9506065
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 9499869
    Abstract: Methods and compositions for the diagnosis, prognosis and/or treatment of ovarian cancer are disclosed.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: November 22, 2016
    Assignee: The Ohio State University
    Inventors: David E. Cohn, Kimberly E. Resnick, Hansjuerg Alder, Carlo M. Croce
  • Publication number: 20160319285
    Abstract: Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.
    Type: Application
    Filed: July 19, 2016
    Publication date: November 3, 2016
    Applicant: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Giulia Romano
  • Patent number: 9480699
    Abstract: Provided are methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. Also provided are methods for determining the efficacy of a cancer therapy in a subject, methods for diagnosing cancer, methods for assessing patient prognosis, and methods for inducing apoptosis of a cell.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 1, 2016
    Assignee: The Ohio State University Research Foundation
    Inventors: Carlo M. Croce, George A. Calin
  • Patent number: 9481885
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Tolllike receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 1, 2016
    Assignee: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Publication number: 20160289683
    Abstract: Methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155 are described.
    Type: Application
    Filed: June 9, 2016
    Publication date: October 6, 2016
    Applicant: The Ohio State University
    Inventor: Carlo M. Croce
  • Publication number: 20160265066
    Abstract: MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: The Ohio State University
    Inventors: Carlo M. Croce, Stefano Volinia